(d) on what basis the eye preparations of Hydrocortisone are in Catagory-I and eye preparations of other corticosteroids are in Category-II?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) To the extent information is available the approved capacity for Hydrocortisone is 361 Kgs. Production of this item is not monitored by this Ministry.

(b) Details of imports are published in the "Monthly Statistics for foreign trade in India", Vol. II, Copies of which are available in the Parliament Library.

(c) Sales turnover of formulations is not monitored.

(d) Eye preparations of Hydrocortisone have been included in Category-I, as per the recommendations of Ministry of Health and Family Welfare whereas eye preparations of other Corticosteroids have been included in Category-II, on the recommendations of Kelkar Committee.

Bulk Drugs for Flucort Range Formulations

4588. SHRI DHARANIDHAR BASUMATARI: Will the Miniser of INDUSTRY be pleased to refer to the answer to Unstarred Question 3289 given in the Rajya Sabha on 22nd August, 1988 and state:

(a) what is the name of the bulk drug on which Flucort range of formulations are based;

(b) what is the CIF price of this drug;

(c) what was the estimated all India sales turnover during 1986 of Flucort range of formulations according to ORG being subscribed by his Ministry;

(d) what is the exclusion criteria on which this drug was excluded from price control by Kelkar Committee; and

(e) what was the price of each Flucort formulations under DPCO, 1979, their present price and the percentage change in each case?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Flucort range of formulations are based on bulk drug Flucinolone acetonide.

(b) The required details to the extent available are given in the Statement (*See* below).

(c) Sales turnover is not monitored.

(d) The Kelkar Committee adopted following five criteria of excluding the drugs.

(i) Exclude those drugs which are not produced in India, provided that the consumption is not significant either now or in the near future.

(ii) To exclude those drugs the turn over of which has been less than rupees fifty lakhs in 1986.

(iii) To exclude all new drugs for which process of manufacture were developed in-

digenously from the price control list at least for the first 5 years.

(iv) To exclude those life-saving drugs and pharmaceutical products whose availability is for more important than the price. As the nature of demand is such that it is required less frequently but its non-availability is fatal. The notable examples of such categories are sera and vaccines.

(v) Exclude those pharmaceutical products of drugs where the domestic production structure is so competitive that there is little possibility that the consumers will be overcharged compared to the cost of production.

(e) As per the provisions of DPCO, 1987, the referred formulations are price decontrolled and the concerned manufacturer is free to revise the prices.

Statement

Name of the formulation	Unit (Kgs.)	1984-85		1985-86		1986-87	
		Quantity	CIF value (Rs.)	Quantity	CIF value (Rs.)	Quantity	CIF value (Rs.)
Fluocinolone Acetonide	—	36	2570208	39	2892839	23	1557496

Notices to Drug Companies

4589. DR. (SHRIMATI) NAJMA HEPTULLA : Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3275 given in the Rajya Sabha on the 22nd August, 1988 and State :

(a) the names of the drug companies to which notices were sent from 1984 to 1987;

(b) the names of the drugs involved in each case ;

(c) what are the details of the follow-up action taken ;

(d) whether his Ministry finalised the amount due from any of the companies;

(e) if so, what are the details thereof ;

(f) whether it is a fact that his Department is deliberately not taking any action despite the powers available under the Essential Commodities Act;

(g) whether any investigation is being proposed to fix responsibility against those responsible for the non-recovery of public money which was overcharged from poor masses of the country; and

(h) if so, by when and if not, what are the reasons therefor?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b)